Table 1.
Patient characteristics.
| Characteristics (n) | Parameters |
|---|---|
| Number of patients | 581 |
| Age (y) (581) | |
| Median | 71 |
| Range | 49–88 |
| Mean ± SD | 71.3 ± 7.5 |
| Gleason Score (581) | |
| ≤ 6 (low risk + grade group 1) | 37 |
| 7 (intermediate risk + grade group 2+3) | 303 |
| 8 (high risk + grade group 4) | 104 |
| > 8 (high risk + grade group 5) | 139 |
| PSA (ng/mL) (581) | |
| Median | 2.98 |
| Range | 0.2–2000 |
| Mean ± SD | 18.21 ± 101.91 |
| PSAvel (ng/mL/y) (196) | |
| Median | 1.24 |
| Range | 0–620.1 |
| Mean ± SD | 10.89 ± 54.25 |
| PSAdt (months) (581) | |
| Median | 10.35 |
| Range | 0–628.2 |
| Mean ± SD | 22.1 ± 48.8 |
| Prior treatment of primary tumor (581) | |
| Surgery (radical prostatectomy) | 493 |
| Radiotherapy and other | 88 |
| Further treatment | |
| Anti-androgen therapy | 209 |
| Positivity rate | |
| Total/PET/CT positive patients | 450/581 |
Abbreviations: PSA, prostate-specific-antigen; vel, velocity; dt, doubling time; SD, standard deviation; n, number of patients; y, year.